MARKET OUTLOOK


With a drug-treated population of more than 4 million people in the United States and EU5, the psoriasis market has been a lucrative space for drug developers,resulting in a plethora of approved agents with diverse mechanisms of action to treat the disease. In recent years, the dynamics of the psoriasis market have started to change; there has been a shift from the use of established TNF-α inhibitors as earlier-line agents to the earlier use of biologics like Stelara. More recently, the approval ofIL-17 inhibitorssuch as Cosentyx and Taltz and IL-23 inhibitors such as Tremfya has resulted in increased pressure on these conventional agents for psoriasis. Nonetheless, the moderate to severe psoriasis early- and late-phase pipeline has several promising agents because drug developers realize that, despite multiple current treatments, an unmet need remains for novel agents that can differentiate themselveson the attributes of efficacy, delivery convenience, and catering to a broad patient population.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals for moderate to severe psoriasis?
  • What drug attributes are key influencers, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals for moderate to severe psoriasis?
  • What are the prevailing areas of unmet need and opportunity in moderate to severe psoriasis?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European dermatologists for a hypothetical new moderate to severe psoriasis drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European dermatologists fielded in January 2019.

Key companies:  AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Merck, Novartis.

Key drugs: Cosentyx, Enbrel, Humira, Otezla, Remicade, Stelara, Taltz, Tremfya.

Table of contents

  • Psoriasis - Unmet Need - Detailed, Expanded Analysis (US & EU)
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Efficacy
        • Safety and Tolerability
        • Convenience of Administration
        • Nonclinical Factors
      • Rationale for Drug Selection
        • Products for Moderate to Severe Psoriasis
    • Treatment Drivers and Goals
      • Key Findings: Attribute Importance
      • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Dermatologists' Prescribing Decisions in Moderate to Severe Psoriasis
      • Importance of Efficacy Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
      • Importance of Efficacy Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
      • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
      • Importance of Convenience of Administration Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
      • Importance of Nonclinical Factors to Prescribing Decisions in Moderate to Severe Psoriasis: United States
      • Importance of Nonclinical Factors to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
      • Key Findings: Stated vs. Derived Importance
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: United States
      • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Moderate to Severe Psoriasis: Europe
    • Product Performance Against Treatment Drivers and Goals
      • Key Findings
      • Overall Performance of Key Therapies for Moderate to Severe Psoriasis: United States
      • Overall Performance of Key Therapies for Moderate to Severe Psoriasis: Europe
      • Mean Overall Performance of Key Therapies for Moderate to Severe Psoriasis: United States and Europe
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Efficacy Attributes: United States
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Efficacy Attributes: Europe
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Safety and Tolerability Attributes: United States
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Safety and Tolerability Attributes: Europe
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Convenience of Administration Attributes: United States
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Convenience of Administration Attributes: Europe
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Nonclinical Attributes: United States
      • Relative Performance of Key Therapies for Moderate to Severe Psoriasis Across Select Nonclinical Attributes: Europe
    • Assessment of Unmet Need
      • Key Findings: Unmet Need in Moderate to Severe Psoriasis
      • Surveyed Dermatologists’ Satisfaction with the Performance of Key Therapies for Moderate to Severe Psoriasis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
      • Surveyed Dermatologists’ Satisfaction with the Performance of Key Therapies for Moderate to Severe Psoriasis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Moderate to Severe Psoriasis: United States
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Moderate to Severe Psoriasis: Europe
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Moderate to Severe Psoriasis: United States
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Moderate to Severe Psoriasis: Europe
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Moderate to Severe Psoriasis: United States
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Moderate to Severe Psoriasis: Europe
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Moderate to Severe Psoriasis: United States
      • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Moderate to Severe Psoriasis: Europe
      • Key Findings: Unmet Need in Moderate to Severe Psoriasis and Related Indications
      • Surveyed Dermatologists' Ascribed Level of Unmet Need in Moderate to Severe Psoriasis and Related Indications: United States
      • Surveyed Dermatologists' Ascribed Level of Unmet Need in Moderate to Severe Psoriasis and Related Indications: Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Moderate to Severe Psoriasis Market and Emerging Therapy Insights
        • Opportunity: A Novel Agent Offering Improved Sustained Efficacy in Moderate to Severe Psoriasis
        • Opportunity: A Novel Agent Offering Efficacy in a Broad Patient Population
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Moderate to Severe Psoriasis Target Product Profile: Attribute Importance
        • PASI 90 Response at Week 16 (% of patients)
        • Maintenance of PASI 75 Response at Week 60 (% of patients)
        • Median Time to PASI 75 Response Rate (weeks)
        • Mean Improvement from Baseline in DLQI Total
        • Rate of Serious Infections (per 100 patient-years)
        • Route and Frequency of Administration
        • Price/Day
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Moderate to Severe Psoriasis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Moderate to Severe Psoriasis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Moderate to Severe Psoriasis Market Simulations: Target Product Profiles Included in Scenario 1
        • Moderate to Severe Psoriasis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Moderate to Severe Psoriasis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Moderate to Severe Psoriasis Market Simulations: Target Product Profiles Included in Scenario 2
    • Appendix
      • Key Abbreviations
      • Experts Interviewed
      • Bibliography

Author(s): Mohit Nasa, MBA

Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.

He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.


Related Reports

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market has become increasingly lucrative owing to the growing use of targeted agents. The dominance of the tumor necrosis factor (TNF

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis Pediatric Psoriasis - Treatment Algorithms - Claims Data Analysis (US)

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management o...

View Details

Psoriasis | Disease Landscape and Forecast | G7 | 2020

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue to dominate the market, their premier posit...

View Details

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details